Can a common blood pressure pill prevent heart attacks after kidney failure in the ICU?

NCT ID NCT05272878

Ongoing Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether irbesartan, a blood pressure medication, can reduce the risk of major heart problems and kidney disease in people who had acute kidney injury while in the intensive care unit (ICU). About 500 adults aged 18-75 will take either irbesartan or a placebo for 12 months after leaving the ICU. The goal is to see if this drug can improve long-term outcomes for these high-risk patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Irbesartan (a blood pressure medication)
What this could lead to: If it works, this could point toward a simple, widely available treatment to reduce heart attacks, strokes, and kidney failure after a serious kidney injury in the ICU.
What could go wrong: This is a phase 3 trial, but it is still early to know if irbesartan will help or cause side effects like low blood pressure. Results may not apply to all kidney injury patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY

Contacts and locations

Locations

Hospital Lariboisière

Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.